FemTab Sequi discontinued

FemTab Sequi (estradiol valerate, levonorgestrel), indicated for hormone replacement therapy for menopausal symptoms and second-line therapy for the prevention of postmenopausal osteoporosis, has been discontinued.

Merck Serono made the decision following low demand for the product. Nuvelle (estradiol valerate, levonorgestrel) is a suitable alternative.

View Nuvelle drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Flu antivirals approved for NHS prescribing as cases increase

Flu antivirals approved for NHS prescribing as cases increase

GPs can now prescribe antiviral medicines for flu prophylaxis...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

New e-cigarette alternative launched on prescription

New e-cigarette alternative launched on prescription

Voke, a new nicotine inhaler, is available to prescribe...

Smoking Cessation Treatment Options

Smoking Cessation Treatment Options

Types and suitabilities of smoking cessation treatments.